National Institutes of Health: Gastrinoma trials
The registry lists 12 Gastrinoma studies with National Institutes of Health as lead sponsor. 0 are open to participants now and 3 have results posted.
Phase 1 2Phase 2 8No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
- Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine CancerCompletedNCT00454363Phase 2Results posted
- Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine TumorsCompletedNCT00131911Phase 2Results posted
- Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaCompletedNCT01204476Phase 1
- Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine TumorsTerminatedNCT00084461Phase 2
- Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine TumorsCompletedNCT00075439Phase 2
- Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
- Treatment of Zollinger-Ellison SyndromeCompletedNCT00001241
- Evaluating Patients With Abnormal Levels of Gastric AcidCompletedNCT00001240
- Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell CancerCompletedNCT00001228Phase 2
- The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric AcidCompletedNCT00001191Phase 2
- Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the PancreasCompletedNCT00001165Phase 2